Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: Insights from the MONA LISA study

Archives of Cardiovascular Diseases

Volumn 106, Issue 2, 2013, Pages 93-102

  Bongard, Vanina ^a,b   Dallongeville, Jean ^c   Arveiler, Dominique ^d,e   Ruidavets, Jean Bernard ^a,b   Amouyel, Philippe ^c   Wagner, Aline ^d   Ferrières, Jean ^a,f  

^a INSERM   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c UNIV LILLE   (France)

^d UNIVERSITÉ DE STRASBOURG   (France)

^e UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^f CHU RANGUEIL   (France)

Author keywords

Cardiovascular risk; Dyslipidaemia; Guidelines; LDL cholesterol; Lipid lowering therapy

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; FEMALE; FRANCE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION; PRACTICE GUIDELINE;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FEMALE; FRANCE; GUIDELINE ADHERENCE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84875462828     PISSN: 18752136     EISSN: 18752128     Source Type: Journal    
DOI: 10.1016/j.acvd.2012.11.003     Document Type: Article

References (22)

1. G. Mancia, G. De Backer, and A. Dominiczak 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J 28 2007 1462 1536
2. J. Perk, G. De Backer, and H. Gohlke European gidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European Society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for cardiovascular prevention and rehabilitation (EACPR) Eur Heart J 33 2012 1635 1701
3. Z. Reiner, A.L. Catapano, and G. De Backer ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 32 2011 1769 1818
4. santé. Haute Autorité de Efficacité et efficience des hypolipémiants: une analyse centrée sur les statines 2012 Haute Autorité de santé Paris, France http://www.has-sante.fr/ portail/upload/docs/application/pdf/2010-09/5-statines-argumentaire-complet-maj- sept-2010.pdf
5. J. Ferrieres, V. Bongard, and J. Dallongeville Trends in plasma lipids, lipoproteins and dyslipidaemias in French adults, 1996-2007 Arch Cardiovasc Dis 102 2009 293 301
6. J. Ferrieres, E.T. Gousse, and C. Fabry Assessment of lipid-lowering treatment in France-the CEPHEUS study Arch Cardiovasc Dis 101 2008 557 563
7. E. Van Ganse, T. Souchet, and L. Laforest Ineffectiveness of lipid-lowering therapy in primary care Br J Clin Pharmacol 59 2005 456 463
8. M. Pigeyre, L. Dauchet, and C. Simon Effects of occupational and educational changes on obesity trends in France: the results of the MONICA-France survey 1986-2006 Prev Med 52 2011 305 309
9. E. Tilloy, D. Cottel, and J.B. Ruidavets Characteristics of current smokers, former smokers, and second-hand exposure and evolution between 1985 and 2007 Eur J Cardiovasc Prev Rehabil 17 2010 730 736
10. A. Wagner, J. Dallongeville, and B. Haas Sedentary behaviour, physical activity and dietary patterns are independently associated with the metabolic syndrome Diabetes Metab 38 2012 428 435
11. A. Wagner, A. Sadoun, and J. Dallongeville High blood pressure prevalence and control in a middle-aged French population and their associated factors: the MONA LISA study J Hypertens 29 2011 43 50
12. R.M. Conroy, K. Pyorala, and A.P. Fitzgerald Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project Eur Heart J 24 2003 987 1003
13. P.W. Wilson, R.B. D'Agostino, and D. Levy Prediction of coronary heart disease using risk factor categories Circulation 97 1998 1837 1847
14. M. Eliasson, U. Janlert, and J.H. Jansson Time trends in population cholesterol levels 1986-2004: influence of lipid-lowering drugs, obesity, smoking and educational level. The northern Sweden MONICA study J Intern Med 260 2006 551 559
15. M. Grau, I. Subirana, and R. Elosua Trends in cardiovascular risk factor prevalence (1995-2000-2005) in north eastern Spain Eur J Cardiovasc Prev Rehabil 14 2007 653 659
16. D.K. Arnett, D.R. Jacobs Jr., and R.V. Luepker Twenty-year trends in serum cholesterol, hypercholesterolemia, and cholesterol medication use: the Minnesota Heart Survey, 1980-1982 to 2000-2002 Circulation 112 2005 3884 3891
17. M.D. Carroll, D.A. Lacher, and P.D. Sorlie Trends in serum lipids and lipoproteins of adults, 1960-2002 JAMA 294 2005 1773 1781
18. P. Marques-Vidal, J.B. Ruidavets, and P. Amouyel Change in cardiovascular risk factors in France, 1985-1997 Eur J Epidemiol 19 2004 25 32
19. prevention. Centers for disease control Total and high-density lipoprotein cholesterol in adults: National Health and Nutrition Examination Survey 2009-2010 2012 Centers for disease control prevention Atlanta, GA, USA http://www.cdc.gov/nchs/data/databriefs/db92.htm
20. J.R. Banegas, E. Lopez-Garcia, and J. Dallongeville Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study Eur Heart J 32 2011 2143 2152
21. J. Dallongeville, J.R. Banegas, and F. Tubach Survey of physicians' practices in the control of cardiovascular risk factors: the EURIKA study Eur J Prev Cardiol 19 2012 541 550
22. J.P. Empana, P. Ducimetiere, and D. Arveiler Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study Eur Heart J 24 2003 1903 1911